

**An investigation of palmyrah fruit pulp mediated inhibition of
intestinal glucose uptake and its toxicity**

By

Deepthi Inoka Uluwaduge



PhD

:

2005

**An investigation of palmyrah fruit pulp mediated inhibition of
intestinal glucose uptake and its toxicity**

By

Deepthi Inoka Uluwaduge

Thesis submitted to the University of Sri Jayewardenapura for the
award of the Degree of Doctor of Philosophy in Biochemistry on
'An investigation of palmyrah fruit pulp-mediated inhibition of
intestinal glucose uptake and its toxicity' on June 2005

DECLARATION BY CANDIDATE

The work described in this thesis, was carried out by me, under the supervision of Prof. E. R. Jansz (Dept. of Biochemistry, Faculty of Medical Sciences, University of Sri Jayewardenepura) and Prof. M. I. Thabrew (Dept. of Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Kelaniya) and a report on this has not been submitted in whole or in part to any University for another Degree/Diploma.

09-01-2006


.....
Date



.....
Signature of candidate

DECLARATION BY SUPERVISORS

We certify that the above statement made by the candidate is true and that this thesis is suitable for submission to the University for the purpose of evaluation.


.....
Prof. E. R. Jansz



.....
Prof. M. I. Thabrew

TABLE OF CONTENTS

	Page No.
I. LIST OF TABLES	xii
II. LIST OF FIGURES	xv
III. LIST OF PLATES	xvii
IV. ABBREVIATIONS	xx
V. ACKNOWLEDGEMENTS	xxii
VI. ABSTRACT	xxv
1. INTRODUCTION	01
1.1 General introduction	01
1.2 Justification and scope of the study	05
1.3 Objectives of the study	08
2. LITERATURE REVIEW	09
2.1 The palmyrah tree and its uses	09
2.1.1 Non edible products	09
2.1.1.1 Trunk/stem	09
2.1.1.2 Petiole	10
2.1.1.3 Sheath	10
2.1.1.4 Stalk	10
2.1.1.5 Leaf	10
2.1.1.6 Seed	11
2.1.1.7 Root	11

2.1.1.8	Seedling	13
2.1.2	Edible products	13
2.1.2.1	Sap based products	13
2.1.2.2	Palmyrah tuber based products	17
2.1.2.3	Fruit based products	20
2.2	Palmyrah fruit pulp (PFP) – Physical and chemical nature	21
2.3	Biomolecules of PFP	24
2.3.1	Pectin and sugar	24
2.3.2	Carotenoids	25
2.3.3	Steroidal saponins	26
2.4	Flabelliferins	27
2.4.1	Isolation	30
2.4.2	Structural elucidation	34
2.4.2.1	The aglycogene	34
2.4.2.2	Flabelliferin I (F-I)	34
2.4.2.3	Flabelliferin II (F-II)	34
2.4.2.4	Flabelliferin B (F _B)	35
2.4.2.5	Flabelliferin C (F _C)	36
2.4.2.6	Flabelliferin D (F _D)	37
2.4.2.7	Flabelliferin N (F _N)	38
2.4.2.8	Flabelliferin E (F _E)	38
2.4.2.9	Flabelliferin F (F _F)	38
2.4.3	The UV active binder associated with PFP	38

2.4.4	Bitter principles in PFP	39
2.4.5	Debittering of PFP	39
2.4.6	Bioactivity	40
2.4.6.1	Saponin like properties	40
	(a) Foam stabilizing activity	40
	(b) Haemolytic activity	41
2.4.6.2	Anti-microbial effects of PFP	41
2.4.6.3	Hypocholesterolaemic effect of PFP	43
2.4.6.4	Antioxidant activity of PFP	44
2.4.6.5	Weight gain studies	44
2.5	Toxic properties of palmyrah flour	45
2.5.1	Neurotoxicity	45
2.5.2	Hepatotoxicity	47
2.5.3	Immunotoxicity	48
2.5.4	Other bioactivities caused by palmyrah flour	48
2.5.5	Detoxification of palmyrah flour	49
2.6	Diabetes mellitus	50
2.6.1	Diagnosis	50
2.6.2	Types of Diabetes mellitus	50
2.6.2.1	Insulin dependent Diabetes mellitus (IDDM)	50
2.6.2.2	Non-Insulin dependent Diabetes mellitus (NIDDM)	52
2.6.3	Treatment of Diabetes mellitus	53
2.6.3.1	Dietary control and physical exercise	53
2.6.3.2	Anti-diabetic drugs and the mechanism of action	54

2.7	Plant extracts with hypoglycaemic properties	57
2.7.1	Sri Lankan plants used in the treatment of diabetes mellitus	57
2.7.2	Active compounds which exert hypoglycaemic activity in medicinal plants	68
2.7.3	Modes of action of oral hypoglycaemic compounds isolated from plants in Sri Lanka and other countries	68
2.8.	Na ⁺ /K ⁺ ATPase pump	72
2.8.1	Mechanism of action	73
2.8.2	Na ⁺ /K ⁺ ATPase dependent glucose transport system in the intestinal cell	73
2.8.3	Inhibitors of the pump (cardiac glycosides)	76
2.9	Use of animal models for bio activity – Important factors to be considered	77
2.9.1	Formulation of animal diet	77
2.9.2	Selection of animals	78
2.9.3	Suitable experimental conditions	78
2.9.4	Animals in toxicity studies	78
3.	MATERIALS AND METHODS	81
3.1	Materials	81
3.1.1	Water	81
3.1.2	Chemicals	81
3.1.3	Enzymes	81

3.1.4	Animals	82
3.1.5	Diabetic patients	82
3.2	Methods	83
3.2.1	Collection of palmyrah fruits	83
3.2.2	Extraction and storage of PFP	83
3.2.3	Determination of the moisture content	85
3.2.3.1	Dean and Stark method	85
3.2.3.2	Air drying in an oven at 105°C	85
3.2.4	Isolation of crude flabelliferins	85
3.2.5	Techniques to separate flabelliferins	87
3.2.5.1	Medium Pressure Liquid Chromatography (MPLC)	87
3.2.5.2	Selective solvent extraction	91
3.2.5.3	Monitoring of fractions	91
3.2.5.4	Preparative TLC	93
3.2.5.5	TLC-Densitometry	95
3.2.5.6	Chromatotron	96
3.2.6	Animal studies	98
3.2.6.1	Housing of animals	98
3.2.6.2	Compounding and pelleting of feed	98
3.2.6.3	Sampling of blood	100
3.2.6.4	Design and procedure of animal experiments	100
3.2.6.5	Administration of extractives and glucose	100
3.2.6.6	Glucose challenge	100

3.2.6.7 Dosage of flabelliferins	101
3.2.6.8 Determination of serum glucose	101
3.2.6.9 Determination of faecal sugar	102
3.2.6.10 Determination of faecal fat	106
3.2.6.11 Collection of intestinal samples and determination of glucose content in the intestinal wash	106
3.2.6.12 Anti-hyperglycaemic activity of PFP	107
3.2.6.13 Effect of 10% PFP containing feed on liver glycogen content of mice	109
3.2.6.14 Anti-hyperglycaemic activity of crude flabelliferins of PFP	110
3.2.6.15 Anti-hyperglycaemic activity of pure flabelliferins separated from crude flabelliferins	112
3.2.6.16 Effect of varying doses of F-II on blood glucose level and intestinal glucose content in mice after a glucose challenge	113
3.2.6.17 <i>In vitro</i> study of the effect of F-II on intestinal Na^+/K^+ ATPase activity	113
3.2.6.18 Toxic effects of PFP	118
3.2.6.18. i Assessment of haematological parameters	118
3.2.6.18. ii Determination key hepatic enzymes	122
3.2.6.18. iii Serum creatinine levels	124
3.2.6.18. iv Determination of the approximate lethal dose of PFP	125

3.2.6.18. v	Short-term toxicity studies	126
3.2.6.18. vi	Long-term toxicity studies	126
3.2.7	Studies with human diabetic subjects	128
3.2.7.1	Patient selection	129
3.2.7.2	Preparation of pinattu	129
3.2.7.3	Extraction of fibre from PFP	129
3.2.7.4	Determination of reducing sugars in pinattu and fibre	133
3.2.7.5	Glucose challenge	133
3.2.7.6	Administration of pinattu	133
3.2.7.7	Administration of fibre	134
3.2.8	HPLC studies on UV active carotenoids bound to F-II	134
3.2.9	Computational evidence for relationship of carbohydrate moiety of flabelliferins with phytofluene	134
3.2.10	Studies on possible stoichiometry of F-II and F _B with phytofluene	135
3.2.11	Attempts to associate phytofluene and F-II (<i>In-vitro</i> study)	135
3.2.11.1	Separation of free phytofluene	135
3.2.11.2	Preparing the column	136
3.2.11.3	UV-spectrum of F-II	136
3.2.11.4	Reaction of phytofluene and F-II	136
3.2.12	Statistical analysis	138

4.0 RESULTS	139
4.1 Moisture content and flabelliferin content of the PFP used for the major study	139
4.1.1 Moisture content	139
4.1.2 flabelliferin content	139
4.2 Anti-hyperglycaemic effect of PFP on animal models	141
4.2.1 Effect of PFP (10%) incorporated feed pellets on weight gain and fasting blood glucose concentration of rats	141
4.2.2 Effect of PFP (10%) incorporated feed pellets on weight Gain and fasting blood glucose concentration of mice	143
4.2.3 Effect of PFP (10%) incorporated feed pellets on post prandial blood glucose concentration (PPBS) and intestinal glucose content in mice after a glucose challenge	143
4.2.4 Effect of PFP (10%) incorporated feed pellets on faecal sugar and faecal fat content after a glucose challenge	146
4.2.5 Effect of PFP (10%) incorporated feed pellets on liver glycogen content of mice	146
4.3 Anti- hyperglycaemic activity of mixed flabelliferins	148
4.3.1 Effect of mixed flabelliferins associated with the UV active binder on weight gain and fasting blood glucose concentration of mice	148
4.3.2 Effect of mixed flabelliferins on faecal sugar content	148

4.3.3	Effect of mixed flabelliferins on blood glucose concentration and intestinal glucose concentration after a glucose challenge	150
4.3.4	Comparison of the anti- hyperglycaemic activities of mixed flabelliferins separated from the UV active impurity with the mixed flabelliferins associated with the UV active impurity	150
4.3.4.1	Effect on the post prandial blood glucose concentration	150
4.3.4.2	Reduction in the intestinal glucose absorption	153
4.4	Anti- hyperglycaemic activity of individual flabelliferins (F-II, F _B , F _D /F _E) separated from the mixed flabelliferins	153
4.4.1	Effect of F-II, F _B , and F _D /F _E on blood glucose concentration after a glucose challenge	153
4.4.2	Effect of F-II on faecal sugar content	153
4.4.3	Effect of F-II, F _B , and F _D /F _E on intestinal glucose absorption after a glucose challenge	154
4.5	Effect of varying doses of pure F-II on blood glucose levels and intestinal glucose content after a glucose load	154
4.6	Effect of F-II (pure and with UV impurity) on Na ⁺ /K ⁺ ATPase activity	157
4.7	Investigations of toxic effects of PFP	160
4.7.1	Tests for LD ₅₀ of PFP	160
4.7.2	Short term toxicity studies –feeding with 10% PFP containing pellets	161

4.10.2 Free carotenoids	182
4.11 Computational evidence for relationship of carbohydrate moiety of flabelliferins with phytofluene	182
4.11.1 Model diagrams for flabelliferin molecules	182
4.11.2 Heat of formation of flabelliferins with phytofluene	182
4.12 Studies on possible stoichiometry of F-II and F _B with phytofluene	188
4.13 Attempts to associate phytofluene with F-II (<i>In-vitro</i> study)	188
5. DISCUSSION	191
6. CONCLUSION	205
7. REFERENCES	206
APPENDIX	

I. LIST OF TABLES

	Page No.	
Table 1.1	Distribution of palmyrah trees in Sri Lanka	03
Table 2.1	Palmyrah fruit pulp composition	23
Table 2.2	The Flabilliferins of PFP	29
Table 2.3	Reference values of blood glucose concentration for the diagnosis of diabetes mellitus and other categories of hyperglycaemia	51
Table 2.4	Medicinal plants used in Sri Lanka for the control of diabetes mellitus	58
Table 2.5	Classes of hypoglycaemic compounds identified from Sri Lankan Medicinal plants	69
Table 2.6	Modes of action through which phytogetic compounds have been shown to exert their hypoglycaemic effects	70
Table 2.7	Feed formula of WHO recommended rat and mice breeding feed	80
Table 3.1	Solvent gradient used to elute F- II	89
Table 3.2	Feed formula of the test feed based on the WHO recommended rat /mouse breeding feed	99
Table 3.3	Concentration gradient of phosphate dilution series	115
Table 3.4	Reaction mixtures of F-II and phytofluene	137
Table 4.1	Food intake and weight gain of weanling rats fed on 10% PFP incorporated feed pellets	142
Table 4.2	Fasting blood glucose concentration (mg/dl) of rats fed on 10% PFP incorporated feed	142

Table 4.3	Mean food intake, mean weight gain and mean fasting blood glucose concentration of mice fed on 10% PFP incorporated feed	144
Table 4.4	Effect of 10% PFP containing feed on intestinal and blood glucose concentration after a glucose challenge (1.5g/KgBW)	145
Table 4.5	Faecal sugar and faecal fat content of mice fed on 10% PFP containing feed	147
Table 4.6	Effect of 10% PFP incorporated pellets on liver glycogen content of mice (assessed in terms of glucose mg/g tissue)	147
Table 4.7	Average weight gain and mean fasting blood glucose concentration of mice after oral administration of mixed flabelliferins	149
Table 4.8	Effects of mixed flabelliferins containing UV binder on blood, intestinal and faecal sugar content after a glucose challenge	151
Table 4.9	Effects of mixed flabelliferins with no UV binder on blood and intestinal glucose concentration after a glucose challenge	152
Table 4.10	Effects of individual flabelliferins (with UV binder) on faecal, blood and intestinal sugar content after a glucose challenge	155
Table 4.11	Effect of pure F-II (0.25mg, 0.5mg, 0.75 mg/mouse) on blood glucose and intestinal glucose concentration after a glucose challenge	156
Table 4.12	Percentage inhibition of Na^+/k^+ ATPase activity exerted by F-II (pure) and F-II (with UV impurity)	158
Table 4.13	IC_{50} values for F-II (pure and with UV compound)	158
Table 4.14	Serum levels of key hepatic enzymes and creatinine levels of mice fed with 10% PFP containing feed for 1 week	162

Table 4.15	Haematological parameters of mice fed with 10% PFP containing feed for 1 week	163
Table 4.16	Serum levels of key hepatic enzymes and creatinine levels of mice fed with 10% or 50% PFP containing feed for 1 month	165
Table 4.17	Haematological parameters of mice fed with 10% or 50% PFP containing feed for 1 month	166
Table 4.18	Mean reduction of post prandial blood glucose (PPBS) concentration of type-II mild diabetic patients after treatment with pinattu and fibre	175
Table 4.19	Crude flabelliferin content and F-II content in 10 different cultivars of PFP	180
Table 4.20	Calculated heats of formation values	187

II. LIST OF FIGURES

	Page No.	
Figure 2.1	Proposed structure of the free steroid isolated by Jeyaratnam	28
Figure 2.2	Proposed structure of the aglycone isolated by Jeyaratnam	28
Figure 2.3	β - sitosterol	34
Figure 2.4	Probable sequence of the bitter flabelliferin.	34
Figure 2.5	Structure of F _B	36
Figure 2.6	Structure of F _C	37
Figure 2.7	Structure of F _D	37
Figure 2.8	Structure of F _N	38
Figure 2.9	Model of Na ⁺ /K ⁺ ATPase structure	74
Figure 2.10	Postulated mechanism of Na ⁺ and K ⁺ transport by the Na ⁺ /K ⁺ ATPase pump	74
Figure 2.11	The transcellular movement of glucose in an intestinal cell	75
Figure 2.12	Chemical structure of Oubain	76
Figure 3.1	D.Waldi's scheme	94
Figure 3.2	Calculation of R _f value	94
Figure 3.3	Standard curve for glucose estimation by DNS method	105
Figure 3.4	Standard curve for P _i determination	116
Figure 4.1	A densitogram showing the flabelliferin profile of the PFP used for the major study	140
Figure 4.2	Percentage inhibitions of Na ⁺ /K ⁺ ATPase activity vs. flabelliferin concentration	159

Figure 4.3	Reduction of post prandial blood glucose concentration (PPBS) mediated by pinattu or fibre with respect to control PPBS value in individual patient (n=20)	176
Figure 4.4	Percentage reduction of post prandial blood glucose concentration (PPBS) after treatment of type-II mild diabetic patients with pinattu (n=20)	177
Figure 4.5	Percentage reduction of post prandial blood glucose concentration (PPBS) after treatment of same patients with fibre isolate (2 nd control) which was equivalent to fibre content of 6g of pinattu (n=20)	177
Figure 4.6	HPLC chart record for the UV compound at 280 nm	183
Figure 4.7	HPLC chart record for the UV compound at 330 nm	183
Figure 4.8	Model diagram of F-II	185
Figure 4.9	Model diagram of F _B	185
Figure 4.10	Model diagram of F _D	186
Figure 4.11	Model diagram of F _E	186
Figure 4.12	Peak area at 280 nm (UV binder) vs. peak area at 500nm (F-II)	189
Figure 4.13	Peak area at 280 nm (UV binder) vs. peak area at 500nm (F _B)	189
Figure 4.14	UV spectrum of phytofluene	190

III. LIST OF PLATES

	Page No.
Plate 1.1 A juvenile palmyrah tree	6
Plate 1.2 A palmyrah groove	6
Plate 1.3 A mature female inflorescence	7
Plate 1.4 A ripe palmyrah fruit	7
Plate 2.1 Rafters from the palmyrah trunk	12
Plate 2.2 Some ornamental products from palmyrah leaf	12
Plate 2.3 Fencing with palmyrah leaves	12
Plate 3.1 A photograph of ICR mice used for the experiments	84
Plate 3.2 Palmyrah fruit pulp enmeshed in fibre	84
Plate 3.3 Extracted palmyrah fruit pulp	84
Plate 3.4 A photograph of a cellulose column	97
Plate 3.5 MPLC apparatus	97
Plate 3.6 The chromatotron	97
Plate 3.7 Manually prepared pellets for the animal studies	132
Plate 3.6 Pinattu, a popular sweet-meat among North – East people of Sri-Lanka	132
Plate 3.7 Fibre extracted from PFP, for the study	132
Plate 4.1a A photomicrograph of liver of control mouse Haematoxylin –eosin $\times 100$	169

Plate 4.1b	A photomicrograph of liver of mouse after 30 days of pellet feed (10%PFP substitution) showing no signs of histopathological lesions.	
	Haematoxylin –Eosin ×100	169
Plate 4.2a	A photomicrograph of liver of control mouse.	
	Haematoxylin –Eosin ×100	169
Plate 4.2b	A photomicrograph of liver of mouse after 30 days of pellet feed (50%PFP substitution) showing no signs of histopathological lesions.	
	Haematoxylin –Eosin ×100	170
Plate 4.3a	A photomicrograph of kidney of control mouse.	
	Haematoxylin –Eosin ×100	170
Plate 4.3b	A photomicrograph of kidney of mouse after 30 days of pellet feed (10%PFP substitution) showing no signs of histopathological lesions.	
	Haematoxylin –Eosin × 100	170
Plate 4.4a	A photomicrograph of kidney of control mouse.	
	Haematoxylin –eosin ×100	170
Plate 4.4b	A photomicrograph of kidney of mouse after 30 days of pellet feed (50%PFP substitution) showing no signs of histopathological lesions.	
	Haematoxylin –Eosin × 100	170
Plate 4.5a	A photomicrograph of intestine of control mouse.	
	Haematoxylin –Eosin ×100	171

Plate 4.5b	A photomicrograph of intestine of mouse after 30 days of pellet feed (10%PFP substitution) showing no signs of histopathological lesions. Haematoxylin –Eosin ×100	171
Plate 4.6a	A photomicrograph of intestine of control mouse. Haematoxylin –Eosin ×100	171
Plate 4.6b	A photomicrograph of intestine of mouse after 30 days of pellet feed (50%PFP substitution) showing no signs of histopathological lesions. Haematoxylin –Eosin ×100	171
Plate 4.7	A photograph of a TLC plate showing major flabelliferins (F _B and F-II) of 10 different cultivars (obtained from different geographical locations), after spraying with anisaldehyde	179
Plate 4.8	A photograph of a TLC plate showing eluents collected correspond to the relative retention time, after spraying with anisaldehyde	184

ABBREVIATIONS

ALP	Alkaline phosphatase
ALT	Alanine transaminase
AOAC	Association of Official Analytical Chemists
AST	Aspartate transaminase
ATP	Adenosine triphosphate
BAW	n- butanol : glacial acetic acid : water
BEN	n- butanol : ethanol : ammonia
DM	Diabetes mellitus
FAB/MS	Fast Atom Bombardment- Mass spectrometry
FBS	Fasting blood sugar
F-I	Flabelliferin tetraglucoside
F-II	Bitter flabelliferin tetraglycoside
F _B	Anti bacterial flabelliferin triglycoside
F _C	Inactive flabelliferin triglycoside
F _D	Inactive flabelliferin diglycoside
F _E	New flabelliferin
F _F	New flabelliferin
F _M	New flabelliferin
F _N	New flabelliferin
γ-GT	Gamma glutamyl transpeptidase
GC	Gas Chromatography
Glc	Glucose
Hb	Haemoglobin concentration
H and E	Haematoxylin and eosin
HPLC	High Performance Liquid Chromatography
IDDM	Insulin dependent diabetes mellitus
MPLC	Medium pressure Liquid Chromatography
MW	Molecular Weight
NIDDM	Non insulin dependent diabetes mellitus
PCV	Packed Cell Volume

PFP	Palmyrah fruit pulp
PPBS	Post prandial blood sugar
¹ H-NMR	Proton Nuclear Magnetic Resonance Spectrometry
RBC	Red blood cell count
Rha	Rhamnose
TLC	Thin Layer Chromatography
WBC	White blood cell count

ACKNOWLEDGEMENTS

I take this opportunity to express my heartiest gratitude to my supervisors Prof. M.I. Thabrew, Senior Professor, Dept. of Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Kelaniya, Ragama and Prof. E.R. Jansz, Senior Professor and Head of the Department of Biochemistry, Faculty of Medical Sciences, University of Sri Jayewardenapura, Nugegoda for their valuable guidance and encouragement and moral support throughout the doctoral programme.

Their never tiring supervision, constructive criticism and valuable suggestions had been a great inspiration enabling me to successfully complete this work throughout many hardships. Dear Madam and Sir it is indeed an honour to be your student, thank you again.

Financial assistance given by NSF/M/02, NSM/M/04 and IPICS: SRI: 07 grants are greatly acknowledged.

I am very thankful to the vice chancellor of University of Kelaniya, Dean of the Faculty of Medicine, University of Kelaniya, former and present Heads of the Dept. of Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Kelaniya for granting me study leave to complete this study.

I am grateful to all the academic staff members of the Dept. of Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Kelaniya for sharing my academic work during my study leave period.

My sincere gratitude goes to Dr. (Mrs.) M.S.A. Perera, Kumari and the other members of the Family Practice Centre, Faculty of Medical Sciences for the kind assistance during the clinical trials.

I am grateful to Dr. P.Jayaweera of the Dept. of Chemistry, University of Sri Jayewardenapura for the guidance and supervision in the Molecular Modeling studies.

My thanks are due to Dr. (Mrs.) S. Yasawardene and Kumudu, Dept. of Anatomy, Faculty of Medical Sciences, University of Sri Jayewardenapura for their support in preparation of tissue sections for histopathological studies.

I extended my warmest gratitude to Dr. (Mrs.) Kamani Fernando and Sujeewa, Dept. of Pathology, Faculty of Medical Sciences, University of Sri Jayewardenapura for their support and guidance in examining tissue sections and Haematological studies.

I am grateful to all the academic staff members of the Dept. of Biochemistry, Faculty of Medicine, University of Sri Jayewardenapura for their numerous support.

I am pleased to acknowledge my research colleagues Dr. Rasika Perera, Buddhika Shiromi, Sevvandi and my senior colleague J.K. Nikawala for their support.

Dear Keerthi and Gayathri 'thank you very much' for the all round support given to me during my hardships.

My thanks are due to Dr. (Mrs) Jayasekera and Dr. (Miss) M. Thammitiyagoda (Animal Section, Medical Research Institute, Colombo) for their support in animal studies.

My sincere gratitude goes to the staff members of the ITI, Colombo for the kind help in preparation of pinattu and allowing me to use Dual wave length flying spot scanning densitometer.

I am pleased to acknowledge the contribution of staff of the Biochemistry laboratory (Faculty of Medical Sciences, University of Sri Jayewardenapura), Research laboratory (Faculty of Applied Sciences, University of Sri Jayewardenapura) and the Animal House (Faculty of Medical Sciences, University of Sri Jayewardenapura) for their willing assistance.

I am thankful to Dr. Nanaja, Dr. Dulani and the staff of the Computer Centre, Faculty of Medicine, and University of Kelaniya for their help during the preparation of the manuscript.

Finally I would like to express my indebtedness to my husband and two kids for their sacrifices, understanding, love and support throughout this study. Special thanks are due to my parents and brothers for their boundless faith and love extended to me in achieving my goals.

An investigation of palmyrah fruit pulp mediated inhibition of intestinal glucose uptake and its toxicity

Deepthi Inoka Uluwaduge

ABSTRACT

Reduced weight gain by Institute of Cancer Research (ICR) mice had been previously reported after feeding 10% palmyrah (*Borassus flabellifer*) fruit pulp (PFP) containing feed. In those studies F-II, a steroidal tetraglycoside of β -sitosterol (MW, 1030) was strongly implicated as the active principle. The objective of this study was to confirm the above, its effect on glucose uptake and determine the mechanism of action and some of the factors affecting this effect.

The study has provided evidence that confirms the weight reducing property of PFP and also demonstrated its ability to inhibit intestinal glucose uptake in mice. Studies showed that feeding of PFP had no effect on fasting blood sugar levels of mice ($p=0.64$) but significantly reduced the liver glycogen content of test mice ($p<0.01$, 11%). A mixture of flabelliferins (dose: 10mg/50g mouse) extracted by the methods described previously on administration to mice after a glucose challenge resulted in a decline in serum glucose levels ($p<0.0001$, 43%), increased intestinal glucose levels ($p<10^{-10}$, 83%) and increased faecal glucose levels ($p<0.01$, 29%). On isolating F-II and other flabelliferins (F_B , F_D/F_E) it was found that only F-II has the ability to lower serum glucose ($p<0.001$, 43%) and increase intestinal glucose ($p<0.001$, 50%). This effect was shown at a dose of 1mg F-II/50g mouse. The findings of the mice study were supported by evidence from a study conducted with mild diabetic type-II patients. In the human study it was decided to use pinattu, a dried PFP which can be classified as fruit leather. The dose of 6g of pinattu (30 mg F-II) was calculated on the basis of IC_{50}

studies and mean human body weight. When pinattu was given to mild, type-II diabetic patients who are not under any therapeutic regimen there was a reduction of 24-48% serum glucose after a glucose challenge (post prandial) when compared with their control (post prandial) values. It has also been shown that the inhibition of intestinal glucose uptake by PFP is mediated mainly by F-II and not by the fibre it contains. A fibre control used in the human study showed that a small part of this is due to fibres (2-11% reduction in serum glucose level) present in PFP.

It has been known for some time that all flabelliferins are bound by a UV active binder. The present study revealed that this binder was comprised of a major carotenoid component identified as phytofluene and a minor component phytoene. Removal of the binder increased the efficiency with which F-II inhibited intestinal glucose uptake even when the dose was reduced to 2 mg mixed flabelliferin/50g mouse.

Inhibition of Na^+/K^+ ATPase activity was found to be a mechanism by which F-II mediates its inhibitory action on intestinal glucose uptake (the IC_{50} values were $9 \times 10^{-5} \text{M}$ and $5 \times 10^{-5} \text{M}$ with and without UV binder respectively). Computational studies showed that the lowering of the inhibition by the binder was probably due to the distortion of the carbohydrate moiety of the F-II, which is strongly connected to the activity the molecule. The beneficial effects of any pharmaceutical agent depend on it being non toxic. Results showed that feeding 10% PFP containing feed for one week (short term) or feeding 10% and 50% PFP containing feed for 30 days (long term) did not show any increase in the levels of key hepatic enzymes viz; alkaline phosphatase, alanine transaminase and aspartate transaminase in the test group when compared with that of the controls. Haematological parameters tested (haemoglobin level, packed cell volume, red cell count and white cell count) were not significantly different in the test

and control groups. Creatinine levels in the test and control groups were not significantly different from each other indicating no renal damage. Microscopic examination of liver, kidney and intestine of test group did not show any pathological changes when compared to those in the control group.

From the overall results it may be concluded that PFP possibly has an application in treating type -II diabetics most probably those that are obese. However the dosage of PFP pinattu must be closely monitored as different PFPs contain different amount of F-II.